<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-055115</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Glutemin levels in patients treated with cisplatin predicts renal failure</dc:title>
<dc:description xml:lang="en">Glutamine is an amino acid (AA) whose mission is carrying nitrogen. Abnormalities        in protein and AA metabolism has been observed in patients with acute        renal failure. Several clinical trials had showed abnormalities in plasma AA and its        elimination in uremic environment. Moreover, renal failure disturbs hepato-splachnic        circulation of glutamin, tyrosine and proline. Cisplatin is a key drug in the chemotherapy        pharmacology, and the nephrotoxicity due to tubular injury, is one of        its most important side effects, which sometimes is irreversible and leads to substitutive renal treatment. The goal of this work is to find predictive factors of renal        failure secondary to cisplatin. Fifty four patients treated with cisplatin were studied.        The plasma AA concentration and another plasmatic and urine parameters        were measured in three different days after each pulse of chemotherapy. Plasma        AA modifications through the pulses and reabsortion percentages of everyone were        analysed too. Significant differences were observed in 13 AA reabsortion percentages        and 16 plasmatic concentration. Glutamin concentration through the pulses        was higher in 13 patients (24%) who presented renal failure (Plasmatic glutamin        concentration higher than 1.000 mM/L at the third day after cisplatin administration        was highly predictive value about getting renal failure, with significant difference        from patients with o normal renal function. Others parameters analysed did        not rise significant predictive values, so as it was not found relation between hyperaminoaciduria        and renal function. It is concluded that cisplatin leads to renal        failure in a 24% of this patients. Glutamin, concentrations higher than 1.000 mM/L        at the third day after cisplatin administration have a high predictive value about        getting renal failure; so, it is suggested this could be a early marker of cisplatin        nephrotoxicity before the serum creatinine is elevated, in order to get an early and        suitable treatment of it</dc:description>
<dc:creator>Cobo, M</dc:creator>
<dc:creator>Benavides, M</dc:creator>
<dc:creator>Martín Gómez, MA</dc:creator>
<dc:creator>Frutos, MA</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La glutamina es un aminoácido encargado del transporte sanguíneo de nitrógeno.        En pacientes que desarrollan insuficiencia renal se ha detectado alteración de        los niveles plasmáticos de aminoácidos (AA) y alteración en su excreción urinaria.        El cisplatino es un fármaco utilizado en quimioterapia, siendo la nefrotoxicidad        uno de sus efectos secundarios más importantes. Con el objetivo de encontrar        factores predictivos para el desarrollo de insuficiencia renal secundaria al        cisplatino, se estudiaron 54 pacientes con diversos tumores en tratamiento con        cisplatino, cuantificándose la concentración de AA y otros parámetros bioquímicos        en plasma y en orina de 24 horas en tres días diferentes tras cada ciclo de        quimioterapia. Se analizaron las variaciones de los AA plasmáticos a lo largo de        los distintos ciclos de cisplatino y los porcentajes de reabsorción de cada uno de        ellos. Se detectaron diferencias significativas a través de los ciclos en el porcentaje        de reabsorción de 13 AA y en las concentraciones plasmáticas de 16. La concentración        de glutamina a lo largo de los ciclos fue mayor en pacientes que desarrollaron        insuficiencia renal. El valor de glutamina sérica &gt; 1.000 mM/L analizada        el tercer día tras la administración de cisplatino fue altamente predictivo de desarrollar        insuficiencia renal, con una diferencia significativa respecto a los pacientes        que no la desarrollan. Se concluye que concentraciones superiores a 1.000        mM/L de glutamina plasmática al tercer día tras la administración de cisplatino        tienen un alto valor predictivo respecto al desarrollo de insuficiencia renal aguda</dc:description>
<dc:source>Nefrologia;27(1): 23-29, ene.-feb. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-055115</dc:identifier>
<dc:title xml:lang="es">Concentraciones de glutamina en pacientes tratados con cisplatino predicen el desarrollo de insuficiencia renal</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d2971^s22020</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d6117^s22062</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50495^s22016</dc:subject>
<dc:subject>^d600^s22062</dc:subject>
<dc:subject>^d4421^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>200702</dc:date>
</metadata>
</record>
</ibecs-document>
